Regulatory Filings • Sep 15, 2022
Regulatory Filings
Open in ViewerOpens in native device viewer
Photocure Partner Asieris announces coverage of Hexvix by the Lecheng Global Specialty Drug Insurance
Press release - Oslo, Norway, September 15, 2022: Photocure ASA (PHO: OSE), The
Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE:
688176) has communicated today on the inclusion of Hexvix[®] in the 2022 edition
of the Lecheng Global Specialty Drug Insurance Specialty Drug List.
As a new specialty drug benefit plan developed under the guidance of the
government covering 40 domestic specialty drugs and 60 overseas specialty drugs,
the Lecheng Global Specialty Drug Insurance allows Hainan citizens access to
more advanced medical resources and comprehensive coverage of their medical
needs.
In December 2021, Hexvix received initial clinical use in the Boao Lecheng
International Medical Tourism Pilot Zone in Hainan Province when the first
prescription in China was issued at Hainan General Hospital, and the first
patient procedure was completed. Asieris received approval from the National
Medical Products Administration (NMPA) for Hexvix to be included in phase III
clinical trials in the first quarter of 2022 as well as a real-world clinical
data pilot study.
Asieris expects the incorporation of Hexvix into the Lecheng Global Specialty
Drug Insurance to help them explore innovative access models, so that innovative
drugs can be introduced into China and covered by commercial insurance earlier
and faster.
Read Asieris' full media release here: Hexvix®, A Diagnostic Drug of Asieris, is
Now Covered by the 2022 Lecheng Global Specialty Drug Insurance - Asieris
Pharmaceuticals (https://asieris.com/hexvix-a-diagnostic-drug-of-asieris-is-now
-covered-by-the-2022-lecheng-global-specialty-drug-insurance/)
Note to editors
All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA
This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.
About Bladder Cancer
Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 720 000 prevalent cases (5-year prevalence rate)[1a],
573 000 new cases and more than 200 000 deaths annually in 2020.[1b]
Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate, with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]
Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all cases and include
the subtypes Ta, carcinoma in situ (CIS), and T1 lesions. In MIBC, the cancer
has grown into deeper layers of the bladder wall. These cancers, including
subtypes T2, T3, and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [January 2022].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. https://www.cancer.org/cancer/bladder-cancer.html
About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)
Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview[ ]improves the detection of tumors and leads to more
complete resection, fewer residual tumors and better management decisions.
Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in
all other markets. Photocure is commercializing Cysview/Hexvix directly in the
U.S. and Europe, and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, New Zealand and Isreal. Please refer
to https://photocure.com/partners/our-partners for further information on our
commercial partners.
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com
For further information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Email: [email protected]
Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: [email protected]
David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: [email protected]
Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.